Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Daily News

PCI for Preventing Death in Unstable vs Stable CAD: New Data, More Soul-searching

Shelley Wood

February 19, 2020

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Guerra de los Medios Británicos: BMJ, Lancet Siguen Recortando el Uso de Estatinas

Todd Neale

September 19, 2016

Advertisement

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Top Coronary Artery Disease News in 2024

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Top Coronary Artery Disease News of 2023

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

PCI for Preventing Death in Unstable vs Stable CAD: New Data, More Soul-searching

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Once Again, ISCHEMIA Trial Feels the Squeeze

TCTMD’s Top 10 Most Popular Stories for December 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Guerra de los Medios Británicos: BMJ, Lancet Siguen Recortando el Uso de Estatinas

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content